Compounding: Groups Tell FDA To Drop “Traditional” and “Non-Traditional” Categories
Stakeholders say it would create more confusion in the pharmacy and regulatory community; they also spar over whether volume, other criteria should be imposed to distinguish compounding types.
You may also be interested in...
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
The agency has the option to issue regulations requiring biologics manufacturers to notify FDA of emerging production problems, but so far it’s only “something that we’re thinking about.”
ANDA action rate dipped below the 90% mandate in second fiscal quarter, another illustration of the effect the pandemic and other issues have on US FDA’s generic drug assessment system.